Steatohepatitis/Metabolic Liver Disease News

CHICAGO — Empagliflozin, an oral SGLT2 inhibitor, may provide substantial benefit to patients with type 2 diabetes and nonalcoholic fatty liver disease by aiding in the reduction of liver fat, according to findings from the E-LIFT trial presented here.

Higher early childhood intake of vitamin E correlated with a lower risk for elevated mid-childhood alanine aminotransferase levels, according to recently published data.

Adults with nonalcoholic fatty liver disease and type 2 diabetes had impaired collagen type 1 C-telopeptide suppression in response to an oral glucose tolerance test but not after an IV glucose infusion, study data show.

Myosteatosis, low BMI and low alanine aminotransferase levels correlate with skeletal volume loss in patients with chronic liver disease, especially among women, according to recently published data.

Specialized chronic disease management for patients with chronic liver disease demonstrated high potential to be more cost-effective than standard care due to fewer patient deaths, according to recently published data.

Data from a study on pediatric nonalcoholic fatty liver disease and nonalcoholic steatohepatitis showed that children with zone 1 steatosis were more likely to have advanced fibrosis and children with zone 3 steatosis were more likely to have steatohepatitis.

The pediatric chronic liver failure sequential organ failure assessment, or pCLIF-SOFA, performed better than Child-Pugh or pediatric end-stage liver disease assessment in predicting 28-day mortality among pediatric patients with decompensated chronic liver disease, according to recently published data.

Measurement of preperitoneal and visceral fat areas with magnetic resonance imaging provided a noninvasive marker to predict liver steatosis and fibrosis in patients with type 2 diabetes at risk for severe nonalcoholic fatty liver disease, according to recently published data.

Researchers discovered an unexpectedly high prevalence of significant liver fibrosis, mostly related to nonalcoholic fatty liver disease, among a general population cohort of individuals with previously unknown liver disease, according to a recently published study.

Patients with nonalcoholic fatty liver disease who consumed modest amounts of alcohol showed less improvement in histologic steatosis and nonalcoholic steatohepatitis compared with patients who abstained entirely, according to recently published data.